Combining Ketamine with Astrocytic Inhibitor as a Potential Analgesic Strategy for Neuropathic Pain. Ketamine, Astrocytic Inhibitor and Pain

• Published in: Molecular pain Vol. 6; no. 1; p. 50
• Main Authors: Mei, Xiao-Peng, Wang, Wei, Wang, Wen, Zhu, Chao, Chen, Lei, Zhang, Ting, Xu, Li-Xian, Wu, Sheng-Xi, Li, Yun-Qing
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 06.09.2010; BioMed Central Ltd; Sage Publications Ltd; BioMed Central; SAGE Publishing
• Subjects: 2-Aminoadipic Acid - administration & dosage; 2-Aminoadipic Acid - pharmacology; 2-Aminoadipic Acid - therapeutic use; Analgesics - administration & dosage; Analgesics - pharmacology; Analgesics - therapeutic use; Animals; Astrocytes - drug effects; Astrocytes - pathology; Confidence intervals; Dosage and administration; Dose-Response Relationship, Drug; Drug therapy; Drug Therapy, Combination; Enzyme inhibitors; Health aspects; Hyperalgesia - complications; Hyperalgesia - drug therapy; Hyperalgesia - pathology; Hyperalgesia - physiopathology; Injections, Spinal; Ketamine; Ketamine - administration & dosage; Ketamine - pharmacology; Ketamine - therapeutic use; Ligation; Male; Medical research; Motor Activity - drug effects; Neuralgia; Neuralgia - complications; Neuralgia - drug therapy; Neuralgia - pathology; Neuralgia - physiopathology; Pain; Phosphorylation; Phosphorylation - drug effects; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate - metabolism; Rodents; Rotarod Performance Test; Spinal Nerves - drug effects; Spinal Nerves - pathology; Statistical analysis; Studies; China
• ISSN: 1744-8069; 1744-8069
• DOI: 10.1186/1744-8069-6-50

Background: Neuropathic pain is an intractable clinical problem. Intrathecal ketamine, a noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist, is reported to be useful for treating neuropathic pain in clinic by inhibiting the activity of spinal neurons. Nevertheless, emerging studies have disclosed that spinal astrocytes played a critical role in the initiation and maintenance of neuropathic pain. However, the present clinical therapeutics is still just concerning about neuronal participation. Therefore, the present study is to validate the coadministration effects of a neuronal noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine and astrocytic cytotoxin L-α-aminoadipate (LAA) on spinal nerve ligation (SNL)-induced neuropathic pain. Results: Intrathecal ketamine (10, 100, 1000 μg/kg) or LAA (10, 50, 100 nmol) alleviated SNL-induced mechanical allodynia in a dose-dependent manner respectively. Phosphorylated NR1 (pNR1) or glial fibrillary acidic protein (GFAP) expression was down-regulated by intrathecal ketamine (100, 1000 μg/kg) or LAA (50, 100 nmol) respectively. The combination of ketamine (100 μg/kg) with LAA (50 nmol) showed superadditive effects on neuropathic pain compared with that of intrathecal administration of either ketamine or LAA alone. Combined administration obviously relieved mechanical allodynia in a quick and stable manner. Moreover, down-regulation of pNR1 and GFAP expression were also enhanced by drugs coadministration. Conclusions: These results suggest that combining NMDAR antagonist ketamine with an astrocytic inhibitor or cytotoxin, which is suitable for clinical use once synthesized, might be a potential strategy for clinical management of neuropathic pain.